Advertisement


Saad Z. Usmani, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.



Related Videos

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 2

During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma?

Recorded April 24, 2020.

Global Cancer Care
COVID-19

Giorgio V. Scagliotti, MD, PhD, on the Oncoming Waves of COVID-19: Italy’s Experience

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the progression of COVID-19 through his community and how, in nursing homes, lack of experience dealing with a pandemic is fueling a third wave of the virus in Italy. Filmed April 15, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 4

At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?

Recorded April 24, 2020.

COVID-19
Global Cancer Care

Jacek Jassem, MD, PhD, on Fighting COVID-19 and Cancer: The View From Poland

Jacek Jassem, MD, PhD, of the Medical University of Gdansk, and an international editor on The ASCO Post Editorial Board, talks about the situation in Poland, how his institution is coping, and the adjustments the staff has made to deliver quality cancer care. Filmed April 17, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement